Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 6, 2006

Microsomal Triglyceride Transfer Protein Inhibitors Patents Cross-licensed

  • Aegerion Pharmaceuticals in collaboration with Pfizer and the University of Pennsylvania entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors.

    Based on the terms of the agreement, Aegerion can independently pursue product-development opportunities involving potential MTP-based therapies to reduce LDL cholesterol. MTP inhibitors have been proven effective in reducing LDL levels in men and women, according to the companies, and are being studied for potential use as monotherapies or in combination with statins or other therapies to reduce LDL cholesterol levels.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »